|
DUBLIN, Feb. 19, 2024 /PRNewswire/ -- The "Biosimilar Lymphocyte Modulator Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.
The global biosimilar lymphocyte modulator market is poised for continued expansion, with projections indicating a rise from $1.71 billion in 2023 to an anticipated $2.86 billion by 2028.
This represents a compound annual growth rate (CAGR) of 10.6%. A significant driver of this growth can be attributed to the increasing incidence of immune-mediated diseases and corresponding treatments involving lymphocyte modulators. The industry has seen heightened awareness among healthcare providers and patients regarding the effectiveness and potential of lymphocyte modulator biosimilars.
North America leads the charge as the largest region within the market, while the Middle East is flagged as the fastest-growing region during the forecast period. The surge in market size and demand is bolstered by several key drivers, including escalating patient interest in biosimilar alternatives, a burgeoning patient demographic, and an amplified call for personalized medicine and minimally invasive procedures.
Innovations and Strategic Moves Fueling Market Dynamics
Innovations in biosimilar technologies and robust quality assurance processes are set to shape the future landscape of the market. Advancements are also being led by an increased focus on patient-centric approaches, with companies such as Fresenius Kabi AG launching Idacio, an adalimumab-aacf biosimilar to Humira, for treating chronic autoimmune diseases.
Autoimmune Diseases Driving Demand
The biosimilar lymphocyte modulator market is further energized by the climb in autoimmune disease cases globally. Reports indicate that these conditions now affect about one in ten individuals, with a higher prevalence observed among women. Biosimilar lymphocyte modulators offer much-needed relief by regulating immune system activity, reducing inflammation, and mitigating symptoms associated with these diseases.
- Key medication types such as Campath-1H and natalizumab biosimilars are central to treating conditions like multiple sclerosis, psoriasis, and leukemia.
- The multiplication of online pharmacies and direct-to-consumer distribution channels are facilitating patient access to these crucial treatments.
- Innovative therapies, like tumor-infiltrating lymphocyte (TIL) immunotherapy, offer promising results in the fight against cancer and are instigating further market growth.
Global Market Insights Offered
The new research report provides key insights into the biosimilar lymphocyte modulator market, offering data on market size, competitive landscape, growth trends, and regional market shares. The report aims to deliver a comprehensive analysis of the current and future market scenarios, ensuring stakeholders are well-informed on the progress and opportunities that this industry presents.
This comprehensive market research reflects the 'factory gate values' of the biosimilar lymphocyte modulator market offerings, emphasizing the revenue generated through sales, grants, and donations. It underscores the importance of consumption values in indicating revenues by organizations within the market's geography, irrespective of the location of production.
The growing biosimilar lymphocyte modulator market delineates the ongoing commitment to advancing healthcare treatments and ensuring these revolutionary therapies are within reach for patients globally. With the market poised for significant growth, the industry stands ready to meet the rising demand and continue its trajectory of innovation and accessibility.
Companies Profiled
- Pfizer Inc.
- Biogen Inc.
- Celltrion Inc.
- Genentech Inc.
- Novartis AG
- Sandoz International GmbH
- Mylan N.V.
- Fresenius Kabi AG
- Biocon Ltd.
- Dr. Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Ltd.
- Lupin Limited
- Stada Arzneimittel AG
- Zydus Cadila
- Hetero Drugs Limited
- Torrent Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd.
- Alvotech
- Coherus BioSciences
- Innovent Biologics
- Shanghai Henlius Biotech
- BioXpress Therapeutics SA
- Mabion SA
- Polpharma Biologics
- Prestige BioPharma
- Qilu Pharmaceutical
- Shanghai Fosun Pharmaceutical Group Co. Ltd.
- Wockhardt Ltd.
- Amega Biotech
For more information about this report visit https://www.researchandmarkets.com/r/e26k6j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
 View original content:https://www.prnewswire.com/news-releases/biosimilar-lymphocyte-modulator-global-market-report-2024---robust-10-6-cagr-forecast-amid-rising-autoimmune-disease-prevalence-302065269.html
SOURCE Research and Markets
|
